DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), has become a pressing global health concern. The complexity of MASLD and the lack of universally effective treatments expose the limitations of current interventions, which focus mainly on lifestyle modifications. Here, we explore the multilayered nature of MASLD, emphasizing its pathophysiology in shaping future medical and lifestyle interventions from a personalized medicine perspective, based on individual molecular profiles. Additionally, we address the limitations of current animal models in reflecting human metabolic syndrome and sex-specific differences. We argue that a holistic approach, integrating social determinants of health, patient preferences, and adherence patterns, is essential for advancing MASLD management effectively., Authors acknowledge continuous funding from the Instituto de Salud Carlos III (ISCIII; currently PI23/00945, DTS22/00010 & DTS24/00035 to J.G.-S., CD21/00095, PI22/01342, PI22/01345 and PI24/02008 to R.G.-D. and M.R.-G., all co-funded by the European Union), the AGAUR-Generalitat de Catalunya (2021 SGR 01322 & 2021 PROD 00036) to J.G.-S and the CIBEREHD. CIBEREHD is funded by the Instituto de Salud Carlos III., Peer reviewed
Proyecto:
ISCIII / Plan Estatal de Investigación Científica PI23
,
ISCIII / Técnica y de Innovación 2021-2023 PI22-01342
,
ISCIII / Plan Estatal de Investigación Científica DTS22
,
ISCIII / Técnica y de Innovación 2021-2023 DTS24
,
ISCIII PI22-01345
,
ISCIII PI24
DOI: http://hdl.handle.net/10261/412891, https://api.elsevier.com/content/abstract/scopus_id/105002740072
HANDLE: http://hdl.handle.net/10261/412891, https://api.elsevier.com/content/abstract/scopus_id/105002740072